Regenerative Biology and Tissue Repair

Introduction to Regenerative Biology

Regeneration—the ability to repair, replace, or re-grow lost or damaged tissues and organs—varies enormously across the tree of life. Planarians (flatworms) can regenerate an entire organism from a small fragment; axolotl salamanders regenerate whole limbs, portions of the heart, and parts of the brain; zebrafish regenerate heart muscle, fins, and spinal cord; adult mammals have limited regenerative capacity—healing skin wounds by scar formation rather than perfect regeneration, and regenerating only specific tissues (liver, intestine, bone marrow). Understanding why mammals regenerate poorly relative to amphibians and the molecular mechanisms enabling superior regeneration in model organisms guides development of regenerative medicine strategies to enhance human repair capacity.

Regenerative medicine aims to replace, restore, or regenerate human cells, tissues, or organs to restore normal function—through cell therapies (transplanting stem cells or differentiated cells), tissue engineering (combining cells with scaffolds to build replacement tissues ex vivo), gene therapies restoring lost function, and strategies stimulating endogenous repair by activating dormant regenerative programmes in adult patient tissues. Advances in iPSC technology, organoid culture, decellularisation approaches, and biomaterial scaffolds are converging to make regenerative therapies increasingly practical for diseases affecting tissues with minimal natural regeneration—heart, spinal cord, retina, and pancreatic beta cells.

Model Organisms for Regeneration

Axolotl Limb Regeneration

Axolotl (Ambystoma mexicanum) limb regeneration proceeds through three major steps: wound healing (skin migration covers the wound within hours); blastema formation (dedifferentiation of muscle, cartilage, skin fibroblasts near the amputation plane, forming a proliferating mass of multipotent progenitor cells—the blastema); and regeneritive outgrowth and patterning (blastema cells re-differentiate and position-specifically reform the entire limb structure). Cell-type-specific lineage tracing using fluorescent proteins demonstrates that dedifferentiated muscle cells re-form muscle, fibroblasts reform connective tissue—suggesting limited transdifferentiation but extensive cell cycle re-entry by differentiated cells. The positional information enabling correct patterning of regenerant digits and structures involves Wnt, BMP, and FGF signalling re-deploying developmental programmes unique to basal tetrapods not silenced in mammals. Connective tissue fibroblast positional memory (HOX code) enables regeneration of correct skeletal structures at each limb level.

Zebrafish Heart Regeneration

Zebrafish regenerate 20% of ventricular myocardium removed by resection within 30 days through cardiomyocyte dedifferentiation, proliferation, and redifferentiation—not through a cardiac stem cell pool. Neonatal mice transiently retain similar regenerative capacity in the first 7 days of life (resectable injury model), then lose this capacity—replaced by scar-forming fibrotic repair. The Hippo/YAP pathway—promoting cardiomyocyte proliferation when active in zebrafish—becomes inactivated in adult mammals as cardiomyocytes terminally exit the cell cycle. YAP1 overexpression in adult mouse cardiomyocytes partially restores proliferative potential after myocardial infarction. Pharmacological inhibition of EGFR and NRG1/ErbB2 signalling, combined with suppression of inhibitory pathways (Hippo, p38 MAPK), partially restores neonatal mouse-like cardiac regeneration in adult hearts in preclinical models.

Mammalian Wound Healing

Phases of Wound Healing

Mammalian wound healing proceeds through four overlapping phases: haemostasis (platelet aggregation, fibrin clot formation within minutes—sealing the wound and providing a provisional ECM matrix); inflammation (neutrophil and macrophage recruitment within hours—clearing bacteria and debris, releasing cytokines [TNF, IL-6] activating subsequent repair responses); proliferation (fibroblast migration and collagen deposition, keratinocyte re-epithelialisation, angiogenesis—peaking at days 3-14); and remodelling (type III collagen replaced by type I collagen, gradual wound contraction by myofibroblasts, scar maturation—months to years). Pathological wound healing manifests as chronic non-healing wounds (diabetic ulcers—impaired macrophage polarisation and angiogenesis) or hypertrophic scars/keloids (excessive fibroblast activation and collagen deposition).

Macrophage Roles in Repair

Tissue-resident and recruited macrophages are essential coordinators of wound healing—ablating myeloid cells causes impaired wound healing. Early wound macrophages (M1-like) produce TNF, IL-1beta, and ROS clearing bacteria and debris; late wound macrophages (M2-like) produce TGF-beta, IL-10, VEGF, and FGF—promoting matrix deposition, angiogenesis, and resolution. Diabetic wounds have a persistent 'stuck' M1 macrophage phenotype failing to transition to pro-repair M2 state—several candidate approaches to force M2 switching (IL-4, IL-10 local delivery, miR-155 inhibition) are in development. Engineered bioactive wound dressings delivering cytokines, miRNAs, or macrophage-attracting signals into wound beds represent a clinically translatable approach to restoring impaired macrophage-mediated healing in diabetic and venous leg ulcers.

Fibrosis vs. Regeneration

The default mammalian response to severe tissue injury is fibrosis—replacement of parenchymal cells with collagen-rich scar tissue synthesised by activated myofibroblasts (from portal fibroblasts, hepatic stellate cells, lung fibroblasts, cardiac fibroblasts). TGF-beta1 is the master pro-fibrotic cytokine—signalling through SMAD2/3 to drive fibroblast-to-myofibroblast transition (alpha-SMA, vimentin, FAP expression), excessive collagen I and fibronectin secretion, and resistance to apoptosis. Fibrosis causes progressive organ dysfunction in liver (cirrhosis), lung (IPF), kidney, heart, and skin (scleroderma). Understanding why some species avoid fibrosis (MRL/lpr superhealer mice, spiny mice Acomys with scar-free skin regeneration) guides identification of anti-fibrotic targets. Macrophage phenotype switching, YAP pathway modulation, and CAF senolysis are anti-fibrotic strategies emerging from comparative regeneration biology.

Examples and Applications

Example 1: Intestinal Regeneration Biology

The intestinal epithelium renews completely every 3-5 days—one of the fastest regenerating tissues in mammals—driven by Lgr5+ crypt base columnar (CBC) stem cells continuously producing daughters that differentiate as they migrate up the crypt-villus axis. After intestinal injury (radiation, infection, inflammation), reserve +4 position quiescent stem cells (Bmi1+, Hopx+, Lrig1+) that survive most injuries can repopulate the Lgr5+ CBC stem cell pool restoring full crypts. Furthermore, secretory progenitors (normally differentiation-committed) can dedifferentiate back to stem cells under severe injury, demonstrating remarkable cellular plasticity in intestinal regeneration. These findings inform management of radiation enteritis, IBD, and chemotherapy-induced gut damage, and guide organoid-based intestinal regeneration therapies using transplanted washed organoid fragments delivering new stem cells to damaged mucosa.

Example 2: Schwann Cell Peripheral Nerve Repair

Peripheral nerves in mammals regenerate successfully after injury through Wallerian degeneration (clearance of distal axon and myelin by Schwann cells acquiring a repair phenotype) followed by axon regrowth guided by Schwann cell-lined bands of Buchner tubes—a specialised cellular scaffold. Repair Schwann cells dedifferentiate from myelinating identity and reprogram to express c-Jun, Shh, GDNF, BDNF, and NCAM promoting axon growth—a remarkable example of mammalian nerve regeneration capacity. Peripheral nerve regeneration rate is ~1 mm/day; successful repair requires accurate axon-target matching. In contrast, central nervous system (CNS) axons fail to regenerate after injury—because CNS myelin proteins (MAG, Nogo-A, OMgp) activate RhoA signalling inhibiting axon growth, and CNS oligodendrocytes do not have the Schwann cell repair phenotype. Identifying the molecular differences and recreating repair Schwann cell functions in CNS (Nogo receptor antagonists, RhoA inhibitors) is a therapeutic approach for spinal cord injury.

Example 3: Planarian Regeneration and Neoblasts

Planarian flatworms can regenerate a complete organism from as few as 100 cells through their neoblasts—the only mitotically active cells in the adult—which are pluripotent adult stem cells constituting ~25% of planarian cells. After amputation, neoblasts near the wound proliferate and form a blastema; position-specific neoblasts expressing HOX genes restore correct anatomy. Molecular dissection of planarian regeneration (by Peter Reddien's, Alejandro Sánchez-Alvarado's labs) using RNAi identified hundreds of regulators including PIWI-homologues (required for neoblast maintenance), stem cell pluripotency factors (nanos, sox2 homologues), and anteroposterior patterning molecules (Wnt system reversed from vertebrates—Wnt signalling specifies the tail, not the head). Planarian systems provide insights about achieving whole-body regeneration from adult stem cells with potential implications for extending mammalian regenerative capacity.

Example 4: Bone Regeneration and Fracture Healing

Bone regeneration after fracture involves periosteal and endosteal progenitor cells (expressing Prx1, Sox9, Osterix markers) forming a callus at the fracture site. Intramembranous ossification directly from progenitor cells contributes at the periosteum; endochondral ossification forms a cartilage template later replaced by bone—both pathways contribute to fracture repair. BMP-2 and BMP-7 recombinant proteins accelerate callus formation (FDA-approved for tibial shaft fractures and spinal fusion). Critical-size bone defects exceeding self-healing capacity are being addressed by bone tissue engineering: decellularised bone scaffolds reseeded with MSCs, 3D-printed hydroxyapatite scaffolds, and in situ gene therapy delivering BMP-2 via adenoviral or lipid nanoparticle vectors. Periosteum transplantation re-establishing the stem cell niche enables critical-size defect repair in some models—the periosteum as a minimally disturbed transplantable regenerative tissue.

Example 5: Spiny Mouse (Acomys) Scar-Free Regeneration

Acomys cahirinus (spiny mouse) regenerates full-thickness skin wounds without scarring—replacing all skin appendages including hair follicles, glands, and dermis. Unlike standard lab mice forming scars, Acomys wounds re-epithelialise faster, recruit fewer fibroblasts, maintain lower TGF-beta signalling, have macrophages that rapidly polarise to anti-inflammatory phenotype, and show extensive extracellular matrix remodelling with controlled collagen deposition. Acomys ear hole wounds (6mm punches) close completely in 30 days with restored vasculature, hair follicles, and cartilage. Comparison of Acomys vs. Mus (scar-forming mice) wound transcriptomes identified reduced fibroblast inflammatory cytokine expression and unique matrix metalloproteinase activity profile as key differences—potential therapeutic targets translatable to reducing human scar formation and keloid treatment.

Example 6: iPSC-Derived Cell Therapies

Induced pluripotent stem cell (iPSC)-derived differentiated cells provide a renewable source for cell transplantation therapies: retinal pigment epithelium (RPE) from iPSCs in clinical trials for dry AMD restoring photoreceptor support; dopaminergic neuron progenitors from iPSCs for Parkinson's disease showing early clinical promise (Blouet/Schüle trials); pancreatic beta cells from iPSCs (Vertex Pharmaceuticals clinical programme showing insulin independence in type 1 diabetes); iPSC-cardiomyocytes for myocardial infarction repair. Key challenges: immune rejection after allogeneic transplantation (HLA-matched iPSC banks; hypoimmunogenic iPSCs with B2M/HLA knockouts and CD47/PD-L1 knock-ins); genetic instability during reprogramming and prolonged culture; tumourigenic risk from incompletely differentiated pluripotent cells co-transplanted with target cells; and ensuring long-term cell engraftment and function at the injury site.

Example 7: Corneal Regeneration

The corneal epithelium is maintained by Lgr5-negative, ABCG2-positive limbal stem cells (LSCs) in the limbal niche at the cornea-sclera border—migrating centripetally to replace shed corneal epithelial cells. Thermal burns, Stevens-Johnson syndrome, or chemical injuries damage the limbal niche causing limbal stem cell deficiency (LSCD)—conjunctival invasion of the corneal surface (pannus), leading to blindness. Autologous LSC transplantation: a small biopsy from the unaffected eye provides LSCs, expanded on fibrin in culture, then transplanted on carrier to the affected cornea—restoring vision in LSCD patients. Holoclar (Chiesi Farmaceutici) became the first stem cell-based cell therapy approved in Europe (2015) for limbal stem cell deficiency. Gene-corrected LSCs for junctional epidermolysis bullosa (LAMB3 mutation corrected by retroviral transduction) permanently reversed the disease in a patient whose body was largely covered by corrected transplanted skin.

Example 8: Organoid Transplantation

Patient-derived organoids transplanted into damaged organs can engraft, expand, and restore function. Mouse colon organoids transplanted into chemically injured colons engraft in the mucosa, differentiate, and regenerate extensive epithelial surface—with complete functional mucosal restoration documented by endoscopy. Human intestinal organoid transplantation after colostomy reversal or IPAA surgery is being tested clinically. Liver organoid transplantation into Wilson's disease mouse models (ATP7B deficiency) after partial hepatectomy engrafted with ~0.5-5% donor liver repopulation—sufficient to correct copper metabolism. Thyroid organoids generated from iPSCs successfully rescued hypothyroid mice after transplantation restoring circulating thyroid hormones. The convergence of organoid technology, precise surgical delivery, and gene correction tools to generate patient-matched corrected organoids for transplantation represents a major frontier in regenerative medicine approaching clinical translation.

Try it live

Everything above runs in your browser — open Regenerative Biology & Tissue Repair Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.